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Abstract
Background: Endometrioid ovarian carcinoma and clear cell ovarian carcinoma are both classified as endometriosis-
associated ovarian cancers (EAOCs). Despite the high rates of recurrence and mortality of EAOC, only a few prognostic
biomarkers have been reported. Mitochondrial superoxide dismutase (SOD2) plays an important role in maintaining
mitochondrial function through oxidative stress tolerance and contributes to chemotherapeutic resistance.
Methods: To clarify the clinical significance of SOD2 in EAOC, SOD2 expression was semi-quantitatively investigated by
immunohistochemical analysis in 61 primary EAOC cases, and the correlations between SOD2 expression and
clinicopathological data and survival were analyzed.
Results: Forty-six (75%) cases expressed high levels of SOD2. High SOD2 expression was associated with a poor
prognosis on both univariate and multivariate analyses after adjusting for variables such as age, International
Federation of Gynecology and Obstetrics (FIGO) stage, blood markers, histological type, and completion of treatment.
There were 14 fatalities from 15 recurrences among 46 cases with high SOD2 expression. In contrast, only one
recurrence and no fatalities were seen among 15 cases with low SOD2 expression.
Conclusion: Increased SOD2 expression is a predictive biomarker for worse prognosis in EAOC. The therapeutic
efficacy of the current standard therapeutic protocol for EAOC is limited; thus, mitochondrial SOD2 should be a
therapeutic target for SOD2-abundant EAOC.
Keywords: Clear cell ovarian carcinoma, Endometrioid ovarian carcinoma, Endometriosis-associated ovarian cancer,
Mitochondrial superoxide dismutase
Background
The incidence of ovarian cancer cases has been increas-
ing, and the current rate is fourfold higher than the rate
40 years ago in Japan [1]. Endometrioid ovarian carcin-
omas and clear cell ovarian carcinomas account for
16.7% and 23%, respectively, of all ovarian cancer cases
in Japan, and they are proportionally much more com-
mon than with ovarian carcinoma subtypes in Europe
and the USA [2, 3]. Endometriosis-associated ovarian
cancer (EAOC) usually occurs in younger women, with
high recurrence and mortality rates [4]. In the clinical
and pathological fields of EAOC, alterations in mismatch
repair proteins and polymerase ε likely identified a sub-
set of EAOCs with excellent outcomes, and abnormal
p53 levels were related to a worse prognosis of EAOC
[5]. Hormone receptor expression was associated with
longer survival with EAOC [6], and glypican-3 was re-
lated to a worse prognosis of ovarian clear cell carcin-
omas [7]. However, further biomarkers predicting the
prognosis are essentially required.
Inflammation and oxidative stress induced by heme
and iron seem to be important triggers in the malignant
transformation of endometriosis into EAOC [8]. EAOC
is regarded as a stress-tolerant cancer because it arises
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from chocolate cysts with a highly oxidative microenvir-
onment, induced by excess heme and chronic inflamma-
tion. In clear cell ovarian carcinoma, abnormalities are
often found in genes responding to oxidative stress and
metabolism of reactive oxygen species (ROS) [9].
Mitochondrial superoxide dismutase (SOD2) is an en-
zyme that metabolizes superoxide in mitochondria and
plays an important role in maintaining mitochondrial
function through oxidative stress tolerance. SOD2 over-
expression correlates with poor prognosis in several can-
cers [10–12]. Suppression of SOD2 enhances ROS
production in ovarian cancer cells and results in in-
creased apoptosis, inhibition of proliferation, and en-
hanced sensitivity to chemotherapy [13]. However, in
ovarian cancer, especially in EAOC, the correlation be-
tween SOD2 expression and prognosis remains un-
known. It is unclear whether overexpression of SOD2 is
strongly involved in ROS resistance and related to prog-
nosis in EAOC. In the present study, we investigated the
correlation between SOD2 expression and prognosis in a
cohort of EAOC cases based on immunohistochemical




Sixty-one patients with EAOC treated at the Department
of Obstetrics and Gynecology, Shiga University of Med-
ical Science Hospital between 1998 and 2017 were en-
rolled in this study. The median patient age at the time
of surgery was 48 (range, 30–80) years. The median
follow-up periods were 66 (range, 1–156) months for
progression-free survival (PFS) and 66 (range, 5–156)
months for overall survival (OS). The endpoint of the
observation period was defined as recurrence or pro-
gression by the last visit to the hospital for PFS and as
death by the last visit to the hospital for OS. All patients
initially underwent surgery and were categorically staged
according to the International Federation of Gynecology
and Obstetrics (FIGO) 2014 criteria. Of 61 patients,
eight did not receive platinum-based adjuvant chemo-
therapy because of patient compliance or complications.
The remaining 53 patients completed standard treat-
ment with platinum-based chemotherapy following max-
imal surgical debulking. Therefore, all patients were
chemotherapy-naive at the time of surgery. Pathological
types of EAOC were 41 clear cell and 20 endometrioid
carcinomas. Patient samples were selected from primary
surgery specimens, including normal ovarian stroma, at
the Shiga University of Medical Science Hospital.
Forty-three cases (70.5%) had accompanying pathologic-
ally (36 cases) or clinically (7 cases) obvious endometri-
osis. Clinical and pathological data, age at diagnosis,
FIGO stage, elevation in blood marker levels (serum
carbohydrate antigen 19-9, serum carbohydrate antigen
125, or serum carcinoembryonic antigen), histological
type, completion of treatment, and follow-up data were
obtained from medical records. All included patients pro-
vided written informed consent. This study was carried
out in compliance with the Declaration of Helsinki and
was approved by the Shiga University of Medical Science
Research Ethics Committee (reference number: 29-178).
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue was used for
SOD2 immunohistochemical analysis. Samples were
sliced into 5-μm sections. After dewaxing, the sections
were autoclaved at 120 °C for 1 min in 10mM sodium
citrate buffer (pH 6.0) and immersed in 0.3% H2O2.
They were then incubated overnight at 4 °C with primary
antibodies against SOD2 (diluted 1:1000, #06-984, Milli-
pore Corporation, Billerica, MA). Sections were rinsed
with phosphate-buffered saline and incubated with sec-
ondary antibody conjugated with horseradish peroxidase
(Simple Stain MAX-PO, Nichirei, Tokyo, Japan) at room
temperature for 1 h. Sections were then stained with
3.3′-diaminobenzidine tetrahydrochloride and counter-
stained with hematoxylin. All slides were scored by two
pathologists blinded to the clinical data, using a standard
light microscope. SOD2 expression in each EAOC was
evaluated by relative comparison to the SOD2 expres-
sion of normal ovarian tissue stromal cells on the same
slide. We categorized tumors into two groups on the
basis of the intensity of SOD2 expression: (1) the high
SOD2 group, wherein the intensity of the tumor cell
staining was stronger than that of normal ovarian stro-
mal cells, and (2) the low SOD2 group, wherein the in-
tensity of the tumor cell staining was less or similar to
normal ovarian stromal cells. As the S/N ratio of immu-
nohistochemical SOD2 expression was quite high, the
scoring of a case was inconsistent between the two pa-
thologists, and the kappa statistic of SOD2 evaluation
was 0.9567682. In one case with inconsistent scoring,
obviously high SOD2 cell levels accounted for about
10% of tumor cells. We considered that such a popula-
tion had a high probability of becoming seeds of recur-
rence or metastases; therefore, this case was eventually
classified into the high SOD2 group.
Statistical analysis
The Kaplan-Meier analysis for PFS and OS were per-
formed using GraphPad PRISM 7 software (GraphPad
Software Inc., La Jolla, CA, USA). All other statistical
analyses were performed with SPSS statistical analysis
software (version 22.0; SPSS Inc., Chicago, IL, USA).
Correlations between SOD2 expression and clinico-
pathological characteristics of the patients were evalu-
ated using the chi-square test or Fisher’s exact test. OS
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and PFS were investigated using the Kaplan-Meier
method. Survival curves were compared using log-rank
and chi-square tests. Prognostic factors for PFS were eval-
uated by univariate and multi-variate analyses using Cox
proportional hazards regression models. PFS intervals
were used as an indicator for the hazard ratio (HR) and
95% confidence interval (CI). Significance was set at 0.05.
Results
Abundant SOD2 expression in EAOC and the correlation
with clinicopathological characteristics
SOD2 expression was semi-quantitatively evaluated in
61 primary tumors of EAOC. Figure 1a–d show exam-
ples of mitochondrial superoxide dismutase (SOD2) ex-
pression in endometriosis-associated ovarian cancers on
immunohistochemical analysis. In both endometrioid
and clear cell carcinomas, SOD2 positivity was seen as
strong dot-like structures in the cytoplasm, suggesting
mitochondrial expression. SOD2 reactivity of normal
ovarian stromal cells was used as an internal control of
each histological section. Cases with stronger SOD2
staining of the tumor cells than normal ovarian stromal
cells were categorized as high SOD2 cases. Among 61
tumors, 46 (75%) tumors expressed high levels of SOD2.
SOD2 expression was not affected by patients’ age,
high FIGO tumor stage (stage 1–2 vs 3–4), presence of
significant blood markers (yes vs no), histology (clear cell
carcinoma vs endometrioid carcinoma), and optimality
of adjuvant primary treatment (yes vs no) (Table 1).
Abundant SOD2 expression can predict poor prognosis in
EAOC
Kaplan-Meier analysis demonstrated the association be-
tween high SOD2 expression and a trend toward shorter
PFS (chi-square value = 3.358, p = 0.0669) and a signifi-
cant correlation with poor OS (chi-square value = 4.198,
p = 0.0405) in EAOC. The 5-year PFS rates in high and
low SOD2 groups were 68.5% and 74.7% and those of
OS in high and low SOD2 groups were 90.0% and 100%,
respectively (Fig. 2). There were 14 fatalities from 15 re-
currences among 46 cases in the high SOD2 group. In
contrast, only one recurrence and no fatalities occurred
among 15 cases in the low SOD2 group, and the single
case of recurrence was completely rescued by chemo-
therapy following salvage surgery.
As cases with low SOD2 levels had notably better
prognoses without any fatalities, it was impossible to
perform Cox regression analysis for OS outcomes. In
this case, we had to apply only PFS evaluation into
the Cox proportional hazards model. On univariate
analysis, high SOD2 expression, incomplete standard
treatment, and high FIGO stage were found to be as-
sociated with poor prognosis. In addition, multivariate
Cox proportional hazards regression analysis con-
firmed that high SOD2 expression was a significant
Fig. 1 Examples of mitochondrial superoxide dismutase (SOD2) expression in endometriosis-associated ovarian cancers on immunohistochemical
analysis. Cases subjected to immunohistochemical analysis for detection of mitochondrial superoxide dismutase (SOD2) expression in clear cell
carcinoma and endometrioid carcinoma are shown in (a, c) and (b, d), respectively. High and low mitochondrial superoxide dismutase (SOD2)
expression levels are demonstrated in (a, b) and (c, d), respectively. Green arrowheads indicate stromal cell areas, where SOD2 was subtly
expressed and used as internal controls. The scale bars correspond to 100 μm
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independent predictive factor for poor PFS (HR = 8.929,
95% CI = 1.151–71.429, p = 0.0362; Table 2), as were
incomplete standard treatment and high FIGO stage.
Discussion
In this study, we identified two clinically important is-
sues. First, the high SOD2 expression of cancer cells is a
poor prognostic factor for EAOC. Second, the current
standard therapeutic protocol is insufficient to achieve
improved survival of patients with EAOC showing high
SOD2 expression.
High SOD2 expression was a worse prognostic factor
for EAOC. SOD2 plays an important role in ROS removal,
whose production is induced by chemotherapeutic treat-
ments, and maintenance of mitochondrial function. In
previous studies, high SOD2 expression is associated with
poor prognosis in some carcinomas [10–12]. Especially in
renal clear cell carcinomas, which show pathological simi-
larities with clear cell ovarian carcinomas, high SOD2 ex-
pression reflects better mitochondrial function and ROS
resistance, and increased SOD2 expression correlates with
poor prognosis [14]. The cancer genome atlas (TCGA)
database cannot suggest that SOD2 is a prognostic indica-
tor in ovarian cancer. However, as the database strongly
depends on the overall incidence of cancer types, the
provisional and final analyses of ovarian cancers have pri-
marily focused on serous ovarian adenocarcinomas, rather
than on EAOC including clear cell and endometrioid
ovarian carcinomas. As EAOC often arises from endomet-
riosis, a tissue abundantly exposed to inflammatory ROS,
it is thought to acquire resistance to oxidative stress.
Hemachandra et al. [15] revealed that SOD2 is more
strongly expressed in ovarian clear cell carcinoma than in
other epithelial ovarian cancer subtypes and that SOD2 is
a pro-tumorigenic or metastatic factor. Hemachandra’s
study conformed to the findings of the present study.
In the present cohort, no patients died in the low
SOD2 expression group, even among patients with high
stage and recurrence. All three patients including those
with tumors with low SOD2 expression, who did not
complete chemotherapy, have not had a relapse until
now. In addition, two patients with high FIGO class and
tumors with low SOD2 expression have survived without
any cancer relapses. Regarding tumors with low SOD2
expression that are highly sensitive to chemotherapeutic
ROS increments, the current standard therapeutic
protocol, i.e., platinum-based chemotherapy following
surgical resection, is considered sufficient. Increased
ROS levels improve the antineoplastic effect of
platinum-based chemotherapy [16]. This fact suggests
that platinum-based chemotherapeutic agents are effect-
ive agents against EAOC with low SOD2 expression.
Conversely, among cases with high SOD2 expression, 15
of 46 cases relapsed and 14 deaths were observed. These
results indicate that the current therapeutic protocol
should be considered insufficient in tumors with high
SOD2 expression. With some anti-cancer agents, such
as cisplatin, ROS are involved in the antitumor effect
[17, 18]. As SOD2 is an antioxidant enzyme that can
prevent oxidative redox-mediated damage of mitochon-
drial proteins and preserve mitochondrial function,
EAOC with high SOD2 expression likely have strong re-
sistance to oxidative stress caused by cancer treatment
such as chemotherapy. In our cohort, SOD2 evaluation
was performed from the sample before each chemother-
apeutic treatment. Therefore, SOD2 may reflect the in-
trinsic aggressive character of the tumor in addition to
the predisposed resistance to chemotherapy. EAOC, es-
pecially ovarian clear cell carcinomas, is well recognized
to have greater resistance to platinum-based chemother-
apy, a more aggressive clinical course, and more
malignant behavior than other types of ovarian cancers
[19–21]. Ovarian clear cell carcinomas have poor prog-
nosis because of resistance to current chemotherapy
protocols, based on platinum and taxane [19].
This study confirmed the following findings: a novel
therapeutic strategy for clear cell ovarian carcinomas
and/or other EAOCs, in which SOD2 is strongly
expressed, should be established. Metformin and other
biguanides, which have been clinically used for the treat-
ment of diabetes mellitus, can inhibit complex I of the
Table 1 Correlation between mitochondrial superoxide
dismutase (SOD2) expression and clinicopathological
characteristics in 61 endometriosis-associated ovarian cancers
Characteristic Cases, n SOD2 expression, n P value
High (n = 46) Low (n = 15)
Age, years
60< 11 10 1 0.2646
≤ 60 50 36 14
FIGO class
Low (I, II) 51 38 13 0.9999
High (III, IV) 10 8 2
Blood marker
Positive 48 37 11 0.7175
Negative 13 9 4
Histology
Clear cell 41 33 8 0.2164
Endometrioid 20 13 7
Treatment
Complete 53 41 12 0.3934
Incomplete 8 5 3
Patients were stratified according to mitochondrial superoxide dismutase
(SOD2) expression. SOD2 expression was not associated with age, International
Federation of Gynecology and Obstetrics (FIGO) stage, blood markers,
histology, or completeness of adjuvant primary treatment
Amano et al. World Journal of Surgical Oncology           (2019) 17:24 Page 4 of 7
Fig. 2 Progression-free (a) and overall (b) survival rates of the groups categorized by mitochondrial superoxide dismutase (SOD2) expression in a cohort
of patients with endometriosis-associated ovarian cancer. A high expression of mitochondrial superoxide dismutase (SOD2) was associated with a trend
toward a shorter progression-free survival (χ2 = 3.358, p = 0.0669) and was correlated significantly with poor overall survival (χ2 = 4.198, p = 0.0405) in
endometriosis-associated ovarian cancers
Table 2 Assessment of clinicopathological parameters predicting progression-free survival on univariate and multivariate analyses
PFS univariate PFS multivariate
n HR (95% CI) p value HR (95% CI) p value
Age 60</≤60 11/50 0.4890 (0.105–2.289) 0.3632
FIGO class III, IV/I, II 10/51 30.303 (7.353–125) < 0.0001 19.608 (5.952–66.667) < 0.0001
Blood marker Positive/negative 48/13 0.806 (0.204–3.185) 0.7583
Histology Clear cell/endometrioid 41/20 2.212 (0.5778–8.475) 0.2463
Standard treatment Incomplete/complete 8/53 6.410 (1.488–27.778) 0.0126 7.576 (1.828–31.25) 0.0052
SOD2 expression High/low 46/15 17.543 (1.825–166.667) 0.0130 10 (1.271–76.923) 0.0287
On univariate analysis, high expression of mitochondrial superoxide dismutase (SOD2), incompleteness of standard treatment, and high International Federation
of Gynecology and Obstetrics (FIGO) stage were associated with poor prognosis. Multivariate Cox proportional hazards analysis also confirmed that high SOD2
expression, incompleteness of standard treatment, and high FIGO stage were significant prognostic factors for worse progression-free survival (PFS). CI confidence
interval, HR hazards ratio
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mitochondrial electron transport chain and mitochon-
drial respiration [22]. In addition, they exert anticancer
effects on patients with diabetes diagnosed with pancre-
atic cancer, colon cancer, and prostate cancer [23–27].
By targeting tumor mitochondrial function, drug reposi-
tioning with the use of biguanides such as metformin
has been proposed for some types of cancers [28]. Isono
et al. [14] demonstrated that biguanide could improve the
therapeutic effect in clear cell carcinomas in the kidney,
which show similar pathology to ovarian clear cell carcin-
omas. Replacement therapy or drug repositioning to target
tumor cell mitochondria, as can be achieved with the use
of biguanides, should be investigated for the treatment of
EAOC with abundant SOD2 expression, which is likely to
retain stronger mitochondrial function.
As this study could not include a huge number of
cases, it was impossible to analyze whether SOD2 was
significantly predictive of the prognosis, after dividing
into each category of FIGO clinical stage or histological
type. Further analyses with more cases and a larger co-
hort of EAOC may be desired. Such studies will provide
more supportive evidences for SOD2 as a predictive bio-
marker for EAOC.
Conclusions
This study demonstrated that SOD2 abundance is a pre-
dictive biomarker for the poor prognosis in EAOC and
highlighted the insufficiency of the current therapeutic
standard against these tumors. Mitochondrial SOD2 should
be regarded as an important therapeutic target for EAOC.
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